Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates
08:45am, Tuesday, 04'th Feb 2025
Regeneron (REGN) came out with quarterly earnings of $12.07 per share, beating the Zacks Consensus Estimate of $11.62 per share. This compares to earnings of $11.86 per share a year ago.
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
08:15am, Tuesday, 04'th Feb 2025
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program, sendin
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
08:11am, Tuesday, 04'th Feb 2025
LOS ANGELES , Feb. 4, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (
Regeneron's earnings boosted by demand for blockbuster eye drug Eylea
08:03am, Tuesday, 04'th Feb 2025
A higher-dose formulation of Eylea saw U.S. sales more than double
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders
07:15am, Tuesday, 04'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Reg
TARRYTOWN, N.Y., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2024 and provided a business up
March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN
06:05am, Tuesday, 04'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit.
Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)
08:00pm, Monday, 03'rd Feb 2025
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November
Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN
05:15pm, Monday, 03'rd Feb 2025
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
Investors can contact the law firm at no cost to learn more about recovering their losses
